Equities Analysts Set Expectations for USANA Health Sciences, Inc.’s Q2 2024 Earnings (NYSE:USNA)

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti Csr dropped their Q2 2024 earnings estimates for USANA Health Sciences in a research report issued on Wednesday, May 1st. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.62 for the quarter, down from their previous estimate of $0.67. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.73 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2024 earnings at $0.64 EPS, Q4 2024 earnings at $0.68 EPS, FY2024 earnings at $2.80 EPS, Q1 2025 earnings at $0.86 EPS, Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.86 EPS and Q4 2025 earnings at $0.88 EPS.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.52 by $0.35. The firm had revenue of $221.08 million during the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a return on equity of 12.94% and a net margin of 6.88%.

A number of other brokerages also recently issued reports on USNA. DA Davidson cut their price target on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating for the company in a report on Thursday, February 22nd. StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 12th.

USANA Health Sciences Trading Up 9.7 %

Shares of USNA opened at $45.55 on Thursday. USANA Health Sciences has a 12-month low of $41.45 and a 12-month high of $69.60. The firm has a market capitalization of $876.38 million, a P/E ratio of 14.19, a P/E/G ratio of 1.27 and a beta of 0.94. The firm has a 50-day moving average price of $46.71 and a 200 day moving average price of $48.44.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, COO Walter Noot sold 5,240 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $49.05, for a total transaction of $257,022.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other USANA Health Sciences news, Chairman Kevin Guest sold 11,011 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $49.00, for a total value of $539,539.00. Following the completion of the transaction, the chairman now owns 10,491 shares in the company, valued at $514,059. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Walter Noot sold 5,240 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $49.05, for a total value of $257,022.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,807 shares of company stock worth $1,200,791. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. increased its stake in shares of USANA Health Sciences by 75.7% during the fourth quarter. Pacer Advisors Inc. now owns 337,371 shares of the company’s stock worth $18,083,000 after buying an additional 145,373 shares during the period. West Coast Financial LLC purchased a new stake in shares of USANA Health Sciences during the 3rd quarter worth $2,469,000. Vanguard Group Inc. lifted its position in shares of USANA Health Sciences by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,567,182 shares of the company’s stock worth $91,853,000 after purchasing an additional 38,533 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of USANA Health Sciences by 58.9% during the first quarter. Assenagon Asset Management S.A. now owns 82,199 shares of the company’s stock worth $3,987,000 after purchasing an additional 30,485 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in USANA Health Sciences by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock valued at $36,323,000 after buying an additional 21,524 shares during the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.